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EDITORIAL
Do kidney tubules serve an angiogenic soup?
The podocyte is an in vivo source of vascular endothe-
lial growth factor (VEGF), and VEGF-A maintains the
morphologic integrity of the normal maturing glomerulus
[1]. More controversial is whether renal tubules express
VEGF, and whether, here, the factor has roles in health or
disease. Do renal tubules express VEGF in vivo? VEGF-
A can be immunodetected in proximal tubules and dis-
tal nephron, where protein levels and distribution can
change markedly after acute tubular necrosis and subto-
tal nephrectomy [2–4]. In these contexts, VEGF-A pro-
tein levels correlate with peritubular capillary behavior,
with either angiogenesis or capillary loss being observed,
depending on the type of insult (e.g., toxic, ischemic, rem-
nant kidney), the time after insult, and the experimental
animal species (e.g., rat or mouse) and strain [2–4]. Kang
et al [3] noted that, in several models of renal disease, the
integrity of peritubular capillaries has a positive correla-
tion with renal function; furthermore, in the rat remnant
kidney, tubular VEGF-A becomes diminished, and the
administration of VEGF-A minimizes loss of peritubular
capillaries and stabilizes renal function [3]. Conversely, in
mouse remnant kidneys, the progression of renal tubular
lesions correlates with a robust angiogenic response by
the peritubular microcirculation associated with an over-
all increase of renal VEGF-A protein [4].
The above data support a functional relationship be-
tween tubular VEGF-A and the state of the adjacent re-
nal cortical microcirculation. A skeptic might, however,
argue that the finding of immunoreactive VEGF-A in
tubules simply reflects the fact that these epithelia take
up the factor from either the tubule lumen or the micro-
circulation; in other words, the data do not prove that
tubules make VEGF-A in vivo. On the other hand, there
are several in situ hybridization studies that support the
idea that renal tubules express VEGF-A transcripts in
health, and that these levels can change after physiologic
stress and in disease states. For example, Simon et al [5] re-
ported that human fetal and adult kidney collecting ducts
expressed VEGF transcripts, Marti and Risau [6] noted
that adult mice expressed the factor in medullary ducts,
and that here, VEGF was up-regulated with systemic hy-
poxia, and Yuan et al [2] found that proximal tubules of
adult mice express VEGF-A transcripts and protein, and
that both were down-regulated after folic acid–induced
acute tubular necrosis.
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To further define factors that modulate the expression
of VEGF-A by renal tubules, investigators have turned
to studies of cultured cells. Kidney tubule cells express
VEGF-A when grown in vitro, and levels of mRNA and
protein can be up-regulated by hypoxia and other stim-
uli, such as transforming growth factor b1, and down-
regulated by interleukins [3, 7, 8]. Binding of active TGFb
to cell surface receptor serine/threonine kinases leads to
a series of biochemical reactions whereby the signal is
transduced to the cell nucleus; this involves the direct
phosphorylation of receptor-mediated Smad 1, 2, 3, 5,
and 8, intracellular proteins which are expressed in most
cells [9]. The expression of Smad 6 and 7 proteins are
more tightly regulated, and these inhibitory Smads are
induced by TGFb in an autoregulatory feedback system
[9].
In a study reported in this issue of Kidney Interna-
tional, Nakagawa et al [10] show that the up-regulation
of VEGF-A expression by rat proximal tubule cells ex-
posed to TGFb1 is linked to the Smad system, and the
authors have additionally begun to explore the complex-
ity of TGFb1 actions with regard to the responses of other
molecules, which themselves modify angiogenesis. These
include: (1) the soluble form of Flt-1 (also called VEGF
receptor type 1), a molecule which binds to VEGF-A but
which does not transduce an angiogenic response; Flt-1,
therefore, acts as a natural antagonist of VEGF-A [11];
and (2) thrombospondin-1 (TSP-1), a molecule which ac-
tivates latent TGF-b1, and which is itself anti-angiogenic
[4]. Nakagawa et al [10] found that TGFb1 increased ex-
pression of both VEGF-A and TSP-1 mRNA and protein
in proximal tubule cells, and also increased Smad 2 and 3
phophorylation/activation. Furthermore, forced overex-
pression of Smad7 inhibited all of these TGFb1-induced
effects. Using cells from mice which were null-mutant for
specific Smad genes, the authors went on to demonstrate
that Smad3 was essential for the VEGF-A response, while
TSP-1 and soluble Flt-1 stimulation required Smad2; a
potential criticism of this part of the study is that fibrob-
lasts, rather than tubular cells, were used. In the last part
of the study, the authors investigated the effects of condi-
tioned media on proliferation of human umbilical venous
endothelial cells as a surrogate marker of “angiogene-
sis.” Media from TGF1b-stimulated Smad2 null-mutant
fibroblasts enhanced proliferation, while media condi-
tioned by Smad3 null-mutant fibroblasts failed to do so.
This was consistent with above observations that the bal-
ance of expressed angiogenic/antiangiogenic factors pre-
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sumably differs between wild-type, Smad2, and Smad3
mutant cells; similar experiments were not, however, re-
ported with null-mutant proximal tubule cells.
So, do kidney tubules serve an angiogenic soup? As
outlined above, there is plenty of evidence that they
express VEGF-A in vivo, where levels correlate with
expansion or regression of peritubular capillaries. Fi-
nal proof for the postulated functional roles of tubule-
derived VEGF-A in health and disease will require the
generation and study of genetically engineered mice in
which VEGF-A is ablated, specifically in parts of the re-
nal tubule (i.e., an inducible Cre-lox system) whereby
VEGF-A is deleted in proximal tubules or collecting
ducts, perhaps using c-glutamyl transpepidase and aqua-
porin 2 promoters to drive Cre recombinase expression.
Similar strategies, with VEGF-A ablated in podocytes,
were informative for understanding glomerular biology
[1]. In addition, the work of Nakagawa et al [10] alerts
us to the fact that kidney tubule cells in vitro, and there-
fore, probably in vivo, also express a range of antian-
giogenic factors; hence, the biological response of an en-
dothelial cells near a tubule will depend on the balance of
epithelial-derived stimulatory and inhibitory factors. The
fact that specific intracellular molecules (e.g., Smad2 and
3) affect this balance suggests a possibility that endothe-
lial responses could be therapeutically shifted towards
angiogenesis (e.g., in states such as kidney tubular atro-
phy associated with capillary loss), or antiangiogenesis
(e.g., in renal cancers where vessels maintain tumor vi-
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